Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1893 2
1894 1
1895 1
1915 1
1995 1
2002 2
2003 3
2004 3
2005 6
2006 4
2007 4
2008 1
2009 2
2010 6
2011 7
2012 1
2013 6
2014 7
2015 6
2016 4
2017 7
2018 7
2019 7
2020 4
2021 4
2022 9
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean james r thompson[Author] (86 results)?
Editorial Comment.
Thompson JE, Stricker PD. Thompson JE, et al. J Urol. 2020 Sep;204(3):495. doi: 10.1097/JU.0000000000000811.01. Epub 2020 Jun 26. J Urol. 2020. PMID: 32589083 No abstract available.
Editorial Comment.
Thompson JE, Stricker PD. Thompson JE, et al. J Urol. 2019 Feb;201(2):306-307. doi: 10.1097/01.JU.0000553007.26960.b9. J Urol. 2019. PMID: 30634362 No abstract available.
In Reply.
Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. Flynn KE, et al. Among authors: thompson je. Oncologist. 2020 Apr;25(4):e744-e745. doi: 10.1634/theoncologist.2019-0890. Epub 2019 Dec 24. Oncologist. 2020. PMID: 31873972 Free PMC article.
JAK protein kinase inhibitors.
Thompson JE. Thompson JE. Drug News Perspect. 2005 Jun;18(5):305-10. doi: 10.1358/dnp.2005.18.5.904198. Drug News Perspect. 2005. PMID: 16193102 Free article. Review.
Putting the rap on Akt.
Thompson JE, Thompson CB. Thompson JE, et al. J Clin Oncol. 2004 Oct 15;22(20):4217-26. doi: 10.1200/JCO.2004.01.103. J Clin Oncol. 2004. PMID: 15483033 Review.
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
Awada H, Abdelmalek M, Cronin T, Baron J, Kashour Z, Azad F, Faisal MS, Faber M, Gravina M, Sung PJ, Green SD, Przespolewski A, Thompson JE, Griffiths EA, Wang ES. Awada H, et al. Among authors: thompson je. Blood Cancer J. 2023 Sep 4;13(1):131. doi: 10.1038/s41408-023-00910-x. Blood Cancer J. 2023. PMID: 37666807 Free PMC article. No abstract available.
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Przespolewski A, Goldberg AD, Talati C, Fazal S, Vachhani P, Sanikommu SR, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Baron J, Griffiths EA, Thompson JE, Sweet K, Wang ES. Przespolewski A, et al. Among authors: thompson je. Blood. 2023 Mar 23;141(12):1489-1493. doi: 10.1182/blood.2022016678. Blood. 2023. PMID: 36493344 Free article. No abstract available.
99 results